CO2020008885A2 - Arilsulfatasa a purificada y composiciones de la misma - Google Patents
Arilsulfatasa a purificada y composiciones de la mismaInfo
- Publication number
- CO2020008885A2 CO2020008885A2 CONC2020/0008885A CO2020008885A CO2020008885A2 CO 2020008885 A2 CO2020008885 A2 CO 2020008885A2 CO 2020008885 A CO2020008885 A CO 2020008885A CO 2020008885 A2 CO2020008885 A2 CO 2020008885A2
- Authority
- CO
- Colombia
- Prior art keywords
- compositions
- arylsulfatase
- purified arylsulfatase
- purified
- mld
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06001—Arylsulfatase (3.1.6.1)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención proporciona, entre otras cosas, métodos de tratamiento de la Enfermedad de Leucodistrofia Metacromática (MLD) y composiciones que comprenden la proteína arilsulfatasa A (ASA) recombinante mediante el uso de terapia de reemplazo de enzimas.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762607831P | 2017-12-19 | 2017-12-19 | |
US201762608569P | 2017-12-20 | 2017-12-20 | |
US201862625814P | 2018-02-02 | 2018-02-02 | |
US201862760597P | 2018-11-13 | 2018-11-13 | |
PCT/US2018/066583 WO2019126376A1 (en) | 2017-12-19 | 2018-12-19 | Purified arylsulfatase a and compositons thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2020008885A2 true CO2020008885A2 (es) | 2020-10-30 |
Family
ID=65024076
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2020/0008885A CO2020008885A2 (es) | 2017-12-19 | 2020-07-17 | Arilsulfatasa a purificada y composiciones de la misma |
Country Status (12)
Country | Link |
---|---|
US (1) | US20200384089A1 (es) |
EP (1) | EP3728572A1 (es) |
JP (2) | JP2021508322A (es) |
KR (1) | KR20200107984A (es) |
CN (2) | CN111699249A (es) |
AU (1) | AU2018393045A1 (es) |
BR (1) | BR112020012637A2 (es) |
CA (1) | CA3086181A1 (es) |
CO (1) | CO2020008885A2 (es) |
MX (1) | MX2020006477A (es) |
RU (1) | RU2020123718A (es) |
WO (1) | WO2019126376A1 (es) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4314997A (en) | 1980-10-06 | 1982-02-09 | Edward Shanbrom | Purification of plasma protein products |
US4315919A (en) | 1980-10-06 | 1982-02-16 | Edward Shanbrom | Depyrogenation process |
US4764369A (en) | 1983-07-14 | 1988-08-16 | New York Blood Center Inc. | Undenatured virus-free biologically active protein derivatives |
US6217552B1 (en) | 1999-03-01 | 2001-04-17 | Coaxia, Inc. | Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma |
EP3875107A1 (en) | 2010-06-25 | 2021-09-08 | Shire Human Genetic Therapies, Inc. | Pharmaceutical formulation comprising a replacement enzyme for a lysosomal enzyme for use in treating lysosomal storage disease intrathecally |
AU2011270670B2 (en) | 2010-06-25 | 2017-01-12 | Takeda Pharmaceutical Company Limited | Methods and compositions for CNS delivery of arylsulfatase A |
JP6427502B2 (ja) * | 2013-01-09 | 2018-11-21 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | アリールスルファターゼaの精製方法 |
MX2018009937A (es) * | 2016-02-17 | 2018-11-29 | Shire Human Genetic Therapies | Metodos y composiciones para administración de arisulfatasa a en el sistema nervioso central (cns). |
-
2018
- 2018-12-19 RU RU2020123718A patent/RU2020123718A/ru unknown
- 2018-12-19 CN CN201880088888.5A patent/CN111699249A/zh active Pending
- 2018-12-19 BR BR112020012637-3A patent/BR112020012637A2/pt unknown
- 2018-12-19 MX MX2020006477A patent/MX2020006477A/es unknown
- 2018-12-19 CN CN202410682584.9A patent/CN118460505A/zh active Pending
- 2018-12-19 CA CA3086181A patent/CA3086181A1/en active Pending
- 2018-12-19 KR KR1020207021051A patent/KR20200107984A/ko not_active Application Discontinuation
- 2018-12-19 JP JP2020533729A patent/JP2021508322A/ja not_active Withdrawn
- 2018-12-19 WO PCT/US2018/066583 patent/WO2019126376A1/en unknown
- 2018-12-19 AU AU2018393045A patent/AU2018393045A1/en active Pending
- 2018-12-19 EP EP18834191.1A patent/EP3728572A1/en active Pending
- 2018-12-19 US US16/955,644 patent/US20200384089A1/en not_active Abandoned
-
2020
- 2020-07-17 CO CONC2020/0008885A patent/CO2020008885A2/es unknown
-
2023
- 2023-09-29 JP JP2023169984A patent/JP2023165991A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2020123718A (ru) | 2022-01-20 |
EP3728572A1 (en) | 2020-10-28 |
CN111699249A (zh) | 2020-09-22 |
CN118460505A (zh) | 2024-08-09 |
BR112020012637A2 (pt) | 2020-12-01 |
CA3086181A1 (en) | 2019-06-27 |
US20200384089A1 (en) | 2020-12-10 |
WO2019126376A1 (en) | 2019-06-27 |
AU2018393045A1 (en) | 2020-07-02 |
JP2021508322A (ja) | 2021-03-04 |
MX2020006477A (es) | 2020-12-10 |
JP2023165991A (ja) | 2023-11-17 |
KR20200107984A (ko) | 2020-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2019014682A2 (es) | Composiciones y métodos para enzimas de internalización | |
DOP2019000180A (es) | INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS | |
CO2021016768A2 (es) | Inhibidores de la autofagia de heteroarilaminopirimidina amida y métodos de uso de estos | |
CO2021016765A2 (es) | Inhibidores de la autofagia de heteroarilaminopirimidina amida y métodos de uso de estos | |
CL2018003582A1 (es) | Composiciones para modular la expresión de c9orf72 (divisional solicitud 201702567) | |
DOP2017000097A (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
BR112021024830A2 (pt) | Vesículas extracelulares microbianas processadas | |
PE20170140A1 (es) | Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer | |
CY1124761T1 (el) | Ρυθμιστες της δραστικοτητας του συμπληρωματος | |
CL2019002368A1 (es) | Composiciones y métodos para el tratamiento de cáncer. | |
UY38003A (es) | Construcciones de arni para inhibir la expresión de pnpla3 y métodos de uso de las mismas | |
UY32812A (es) | Anticuerpos humanos de alta afinidad para angiopoyetina -2 humana. | |
CL2021000909A1 (es) | Anticuerpos estabilizadores de trem2 | |
MX2020004712A (es) | Vesiculas extracelulares modificadas geneticamente con proteinas. | |
CO2019002889A2 (es) | Tratamientos de combinación que comprenden la administración de imidazopirazinonas | |
CO2022000481A2 (es) | Inhibidores de enzimas | |
BR112019007210A2 (pt) | métodos e composições para o tratamento da doença de fabry | |
CO2022000260A2 (es) | Inhibidores de la autofagia de la amida aminopirimidina y sus métodos de uso | |
CO2022007814A2 (es) | Ligandos de la pseudoquinasa tyk2 | |
MX2021006945A (es) | Anelosomas para suministrar modalidades terapéuticas de reemplazo de proteínas. | |
ECSP22019177A (es) | Proteínas de fusión nkg2d y sus usos | |
CO2021003136A2 (es) | Terapias de combinación | |
BR112017015613A2 (pt) | gel intestinal de levodopa e carbidopa e métodos de utilização | |
CL2020000127A1 (es) | Moduladores terapéuticos del modo inverso de la atp sintasa. | |
CO2020008885A2 (es) | Arilsulfatasa a purificada y composiciones de la misma |